Intravenous Dexmeditomidine for Prevention of Spinal Anesthesia Induced Shivering.

Sponsor
Rehman Medical Institute - RMI (Other)
Overall Status
Recruiting
CT.gov ID
NCT05342376
Collaborator
(none)
80
1
2
10.9
7.3

Study Details

Study Description

Brief Summary

Intraoperative and post operative shivering is a common problem encountered in operating rooms and recovery suites. Shivering under spinal anesthesia has an incidence of 40-60%. Shivering is not only uncomfortable for the patient; additionally it increases minute oxygen consumption, subjecting the patient to a higher risk of cardiovascular complications. A variety of drugs like pethidine, fentanyl, alfentanil, sufentanil, buprenorphine, doxapram, clonidine, and ketanserin, are reported to be effective in suppressing postoperative shivering, yet an ideal drug/ method to be explored. Dexmeditomidine, a sedative and analgesic, may control shivering without significant adverse effects, like nausea and vomitting and respiratory depression.

The study design will be randomized controlled parallel trials with sample size of 80,They will be randomized into two equal groups. One group will receive 10 microgram Inj. Dexmeditomedine while the other will recieve inj. normal saline as placebo. The participants will be assessed for intra- and postoperative shivering.

Condition or Disease Intervention/Treatment Phase
  • Drug: Dexmedetomidine Hydrochloride
  • Drug: Normal Saline
Phase 4

Detailed Description

Intraoperative inadvertent changes in the body temperature are quite common. Incidence of inadvertent hypothermia (up to 90%) is much higher than hyperthermia. The hypothermic patients shiver postoperatively after general anesthesia and both introperatively and post operatively during regional anesthesia. Shivering under spinal anesthesia has an incidence of 40-60%. Shivering is not only uncomfortable for the patient; additionally it increases minute oxygen consumption VO2 at the cost of increased presser hormones level, subjecting the patient to a higher risk of cardiovascular complications. Heat loss from skin and surgical site is mostly by radiation. Dropped body temperature in cesarean section under spinal anesthesia is due to a combination of anesthetic-induced impaired thermoregulation i.e. vasodilation and inhibition of vasoconstriction in the blocked dermatomes, which are due to autonomic and motor blockade caused by spinal anesthesia. General anesthesia also leads to hypothermia due to vasodilation and reduced metabolic rate, in the order of 20%-30%. Additional factors are exposure to cold environment, un-warmed cold irrigants/ intra vascular fluids and ventilation with dry anesthetic gases. In spinal anesthesia, due to blocked motor activity below umbilicus, shivering in response to hypothermia is abolished. It interferes with physiologic heat recovery, as human core body temperature should normally be maintained within the narrow range of 36.5-37.5 °C. A variety of drugs like pethidine, fentanyl, alfentanil, sufentanil, buprenorphine, doxapram, clonidine, and ketanserin, are reported to be effective in suppressing postoperative shivering, yet an ideal drug/ method to be explored. Dexmeditomidine which is an alpha-2 agonist, is a new drug used for analgesia and sedation either in perioperative settings or in intensive care units. It is 7-8 times selective alpha 2 agonist than clonidine and was expected to control shivering like clonidine. There are study demonstrating the favorable effect of Dexmeditomidine via infusion in the intraoperative period on shivering after abdominal hysterectomy. In previous studies, a prophylactic single dose of Dexmeditomidine for prevention or aborting shivering was generally found to be effective after general or regional anesthesia. Dexmedetomidine 0.5 mcg/kg I/v as loading dose was found 100% effective in managing post anesthesia shivering after general anesthesia in children. In another study, it was observed that Dexmedetomidine was equally effective compared to tramadol, and was associated with shorter time for complete shivering control and less incidence of nausea vomiting, but prospects of a single sub loading dose in parturients during spinal anesthesia requires exploration as physiologic volume loaded parturients at term are expected to lose more heat by redistribution due to vasodilation caused by spinal anesthesia.

OBJECTIVE: To determine the role of single sub loading dose of Dexmeditomidine i.e. 10 mcg (0.1- 0.2 microgram/kg) administered intravenously for prevention of shivering in participants undergoing Cesarean section under spinal anesthesia in a randomized double-blind, placebo controlled parallel study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Parallel Assignment The study design is prospective double-blinded randomized controlled parallel trial with allocation ratio of 1:1.Parallel Assignment The study design is prospective double-blinded randomized controlled parallel trial with allocation ratio of 1:1.
Masking:
Double (Participant, Care Provider)
Masking Description:
Two color coded envelops containing drug and placebo.
Primary Purpose:
Prevention
Official Title:
Role of Dexmeditomidine HCL for Prevention of Shivering in Obstetrical Spinal Anesthesia, a Randomized Controlled Double Blind Parallel Study.
Actual Study Start Date :
Feb 1, 2022
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Dexmedetomidine

This is group D, which will receive 10 micro-gram Dexmeditomidine diluted in 02 ml normal saline to be administered intravenously in 10 minutes after umbilical cord is clamped..

Drug: Dexmedetomidine Hydrochloride
The parturients will receive 10 micro-gram Dexmedetomidine diluted in 02 ml normal saline to be administered intravenously over 10 minutes after umbilical cord is clamped..
Other Names:
  • inj Precidex (brookes pharmaceutical, Pakistan)
  • Active Comparator: Saline

    This group S will receive 02 ml normal saline intravenously as placebo in 10 minutes after umbilical cord is clamped..

    Drug: Normal Saline
    The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
    Other Names:
  • Normal Saline 0.9 %
  • Outcome Measures

    Primary Outcome Measures

    1. Rate of shivering in all parturients who received either Dexmeditomidine HCL or placebo [Two hours]

      The intensity of postoperative shivering will be graded using Bedside Shivering Assessment Scale(BSAS) from 0 - 3 with 0= no shivering and 3=severe shivering.

    Secondary Outcome Measures

    1. Rate of sedation in all parturients who received either Dexmedetomidine HCL or placebo. [Two hours]

      Sedation will be assessed through Richmond agitation sedation scale (RASS) from +4 to - 5 with +4= combative and -5= unarousable.

    2. Rate of postoperative pain and analgesia in all parturients who received either Dexmeditomidine HCL or placebo. [Two hours]

      Postoperative pain/analgesia will be assessed through visual analogue scale (VAS) with 0= no pain, 100= very severe pain.

    3. Incidence of adverse reactions associated with Dexmedetomidine HCL [Two hours]

      Incidence of adverse reactions like hypotension and bradycardia in Dexmedetomidine group will be noted and compared with saline group

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion criteria:
    • American Society of Anesthesiologists (ASA) physical status I and II ladies

    • Singleton pregnancies.

    • Undergoing elective Cesarean delivery under spinal anesthesia.

    • Systolic blood pressure ≥ 100 mm of Hg after umbilical cord clamping

    Exclusion criteria:
    • ASA class III or above

    • Hyperthyroidism

    • Cardiopulmonary or respiratory disease

    • A psychological disorder

    • An initial body temperature of >37.5 °C or <36.5 °C

    • Systolic blood pressure <100 mm of Hg after umbilical cord clamping and/or mean arterial pressure (MAP) < 65 mm of Hg after umbilical cord clamping

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Rehman Medical Institute Peshawar Khyber Pakhtunkhwa Pakistan 25000

    Sponsors and Collaborators

    • Rehman Medical Institute - RMI

    Investigators

    • Principal Investigator: Mohammad Shafiq, FCPS, Rehman Medical Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Mohammad Shafiq, Consultant Anesthesiologist, Rehman Medical Institute - RMI
    ClinicalTrials.gov Identifier:
    NCT05342376
    Other Study ID Numbers:
    • RMI/RMI-REC/Approval/58
    First Posted:
    Apr 22, 2022
    Last Update Posted:
    May 11, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 11, 2022